Songdo, Incheon, South Korea – [Date] – Celltrion, a leading global biopharmaceutical company, announced today that it has initiated commercial production of drug substance at its newly constructed third plant in Songdo. The state-of-the-art facility, which was completed in November 2022, is designed to meet the growing demand for biopharmaceuticals and enhance the company's production capabilities.

With a total production capacity of 60,000 liters, the third plant complements Celltrion's existing facilities and brings the company's overall production capacity to an impressive 250,000 liters. The new plant is optimized for small-batch, multi-product production, allowing Celltrion to respond swiftly to evolving market needs and develop a diverse range of biopharmaceuticals.

"The third plant represents a significant milestone in Celltrion's journey to become a global leader in biopharmaceuticals," said [Name], [Title] at Celltrion. "By focusing on high-titer production and adopting innovative manufacturing processes, we are able to produce a greater quantity of high-quality biopharmaceuticals from the same amount of culture medium, enhancing our cost-effectiveness and competitiveness."

Celltrion has also invested in advanced technologies and equipment to improve efficiency and ensure product quality. The company has implemented a high-concentration dilution method in the purification process and localized certain equipment to enhance maintainability.

Looking ahead, Celltrion is set to further expand its manufacturing capabilities with the construction of a new drug product plant, which is scheduled for completion in 2026. This additional facility will enable Celltrion to provide a comprehensive range of biopharmaceutical products to patients worldwide.